Changing the History of Prostate Cancer with New Targeted Therapies

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) treatment is evolving with targeted therapies.
• Alterations in DNA repair genes, particularly homologous recombination (HR) genes, occur in 20-25% of mCRPC cases, correlating with aggressive disease.
• Poly ADP ribose polymerase inhibitors (PARPi) show efficacy in HR-deficient mCRPC, but resistance and BRCA wildtype tumors do not benefit.

Purpose of the Study:

• To review novel therapeutic strategies for improving outcomes in prostate cancer patients.
• To explore emerging biomarkers and targeted therapies beyond classic androgen receptor (AR) pathways.
• To discuss approaches for overcoming resistance to current therapies and enhancing treatment efficacy.

Main Methods:

• Review of recent scientific literature and clinical studies.
• Analysis of emerging targeted therapies and drug combinations.
• Focus on molecular subtypes and predictive biomarkers in mCRPC.

Main Results:

• PARP inhibitors (PARPi) are effective in mCRPC with HR gene alterations.
• Tumors resistant to PARPi or with wildtype BRCA do not benefit from PARPi monotherapy.
• Investigational strategies include combining PARPi with PI3K or AKT inhibitors to induce BRCAness and synthetic lethality.

Conclusions:

• Targeted therapies and combination strategies hold promise for overcoming resistance in mCRPC.
• Understanding molecular subtypes and biomarkers is crucial for personalized prostate cancer treatment.
• Further research into novel drug combinations, like PARPi with PI3K/AKT inhibitors, is essential to improve patient outcomes.